SGI‐110/NCT01696032.
Trial name or title | A randomised, controlled, open‐label, phase 2 trial of SGI‐110 and carboplatin in subjects with platinum‐resistant recurrent ovarian cancer |
Methods | Phase II open‐label RCT |
Participants | 116 women with PR ROC |
Interventions | SGI‐110 + carbo versus PLD (40 mg/m²) or TOP or paclitaxel |
Outcomes | Primary; SAE, PFS, CA125 Secondary: ORR, duration of response, OS |
Starting date | Oct 2012 |
Contact information | Astex Pharmaceuticals; Medpace Recruitment Center |
Notes | End Date: Jul 2014 |